Literature DB >> 24219051

Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature.

Helen McTaggart-Cowan1, Paulos Teckle, Stuart Peacock.   

Abstract

Cancer-specific health-related quality of life instruments are often used to evaluate the patients' quality of life in clinical trials. However, these instruments cannot be used in economic evaluation to guide resource allocation decisions. Mapping is an approach that enables utilities to be predicted for use in cost-utility analysis. The purpose of this study was to review the literature on the mapping methods used to determine utilities from two cancer-specific instruments. Thirteen studies were identified and a total of 53 models were reported. Most of the studies employed an ordinary least squares method and did not conduct an out-of-sample validation. There is a need for more rigorous and robust mapping studies to be conducted to ensure appropriate funding recommendations are being made.

Entities:  

Mesh:

Year:  2013        PMID: 24219051     DOI: 10.1586/14737167.2013.850420

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  10 in total

1.  Health related quality of life in patients with bladder cancer: a cross-sectional survey and validation study of the Hungarian version of the Bladder Cancer Index.

Authors:  Noémi V Hevér; Márta Péntek; András Balló; László Gulácsi; Petra Baji; Valentin Brodszky; Miklós Damásdi; Zita Bognár; György Tóth; István Buzogány; Árpád Szántó
Journal:  Pathol Oncol Res       Date:  2014-12-01       Impact factor: 3.201

2.  The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study.

Authors:  Helen McTaggart-Cowan; Madeleine T King; Richard Norman; Daniel S J Costa; A Simon Pickard; Rosalie Viney; Stuart J Peacock
Journal:  Health Qual Life Outcomes       Date:  2022-06-16       Impact factor: 3.077

3.  QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.

Authors:  M T King; D S J Costa; N K Aaronson; J E Brazier; D F Cella; P M Fayers; P Grimison; M Janda; G Kemmler; R Norman; A S Pickard; D Rowen; G Velikova; T A Young; R Viney
Journal:  Qual Life Res       Date:  2016-01-20       Impact factor: 4.147

4.  Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.

Authors:  J Diels; P Hamberg; D Ford; P Wheatley Price; M Spencer; R N Dass
Journal:  Qual Life Res       Date:  2014-10-19       Impact factor: 4.147

5.  Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach.

Authors:  Daniel Sj Costa; Neil K Aaronson; Peter M Fayers; Peter S Grimison; Monika Janda; Julie F Pallant; Donna Rowen; Galina Velikova; Rosalie Viney; Tracey A Young; Madeleine T King
Journal:  Patient Relat Outcome Meas       Date:  2014-11-06

6.  Assessing Health-Related Quality of Life of Chinese Adults in Heilongjiang Using EQ-5D-3L.

Authors:  Weidong Huang; Hongjuan Yu; Chaojie Liu; Guoxiang Liu; Qunhong Wu; Jin Zhou; Xin Zhang; Xiaowen Zhao; Linmei Shi; Xiaoxue Xu
Journal:  Int J Environ Res Public Health       Date:  2017-02-23       Impact factor: 3.390

7.  Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.

Authors:  Madeleine T King; Rosalie Viney; A Simon Pickard; Donna Rowen; Neil K Aaronson; John E Brazier; David Cella; Daniel S J Costa; Peter M Fayers; Georg Kemmler; Helen McTaggart-Cowen; Rebecca Mercieca-Bebber; Stuart Peacock; Deborah J Street; Tracey A Young; Richard Norman
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

8.  Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.

Authors:  Paulos Teckle; Helen McTaggart-Cowan; Kim Van der Hoek; Stephen Chia; Barb Melosky; Karen Gelmon; Stuart Peacock
Journal:  Health Qual Life Outcomes       Date:  2013-12-01       Impact factor: 3.186

9.  Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?

Authors:  Ann-Jean C C Beck; Jacobien M Kieffer; Valesca P Retèl; Lydia F J van Overveld; Robert P Takes; Michiel W M van den Brekel; Wim H van Harten; Martijn M Stuiver
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

10.  Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.

Authors:  Aureliano Paolo Finch; Eva Gamper; Richard Norman; Rosalie Viney; Bernhard Holzner; Madeleine King; Georg Kemmler
Journal:  Pharmacoeconomics       Date:  2021-07-03       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.